Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 199

Similar articles for PubMed (Select 23313564)

1.

Brain-derived neurotrophic factor in generalized anxiety disorder: results from a duloxetine clinical trial.

Ball S, Marangell LB, Lipsius S, Russell JM.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:217-21. doi: 10.1016/j.pnpbp.2013.01.002. Epub 2013 Jan 10.

PMID:
23313564
2.

Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China.

Wu WY, Wang G, Ball SG, Desaiah D, Ang QQ.

Chin Med J (Engl). 2011 Oct;124(20):3260-8.

PMID:
22088518
3.

Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.

Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, Rickels K, Raskin J.

Depress Anxiety. 2008;25(3):182-9.

PMID:
17311303
4.

Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment.

Pollack MH, Endicott J, Liebowitz M, Russell J, Detke M, Spann M, Ball S, Swindle R.

J Psychiatr Res. 2008 Oct;42(12):1042-9. doi: 10.1016/j.jpsychires.2007.11.006. Epub 2008 Jan 24.

PMID:
18221755
5.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
6.

BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.

Ninan PT, Shelton RC, Bao W, Guico-Pabia CJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:86-91. doi: 10.1016/j.pnpbp.2013.09.016. Epub 2013 Oct 2.

PMID:
24096053
7.

Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials.

Allgulander C, Hartford J, Russell J, Ball S, Erickson J, Raskin J, Rynn M.

Curr Med Res Opin. 2007 Jun;23(6):1245-52. Epub 2007 Apr 25.

PMID:
17559726
8.

Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint.

Pollack MH, Kornstein SG, Spann ME, Crits-Christoph P, Raskin J, Russell JM.

J Psychiatr Res. 2008 Oct;42(14):1176-84. doi: 10.1016/j.jpsychires.2008.02.002. Epub 2008 Mar 17.

PMID:
18348888
9.

Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms.

Russell JM, Weisberg R, Fava M, Hartford JT, Erickson JS, D'Souza DN.

Depress Anxiety. 2008;25(7):E1-11.

PMID:
17587217
10.

Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.

Sheehan DV, Harnett-Sheehan K, Spann ME, Thompson HF, Prakash A.

Int Clin Psychopharmacol. 2011 Mar;26(2):75-83. doi: 10.1097/YIC.0b013e328341bb5f.

PMID:
21102344
11.

Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial.

Alaka KJ, Noble W, Montejo A, DueƱas H, Munshi A, Strawn JR, Lenox-Smith A, Ahl J, Bidzan L, Dorn B, Ball S.

Int J Geriatr Psychiatry. 2014 Sep;29(9):978-86. doi: 10.1002/gps.4088. Epub 2014 Feb 20.

12.

The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder.

Sheehan DV, Meyers AL, Prakash A, Robinson MJ, Swindle RW, Russell JM, Mallinckrodt CH.

Curr Med Res Opin. 2008 Sep;24(9):2457-66. doi: 10.1185/03007990802293643 . Epub 2008 Jul 24.

PMID:
18662492
13.

The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?

Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM.

J Clin Psychiatry. 2004 Apr;65(4):521-30.

PMID:
15119915
14.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.

Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70.

PMID:
15589385
15.

Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial.

Davidson JR, Wittchen HU, Llorca PM, Erickson J, Detke M, Ball SG, Russell JM.

Eur Neuropsychopharmacol. 2008 Sep;18(9):673-81. doi: 10.1016/j.euroneuro.2008.05.002. Epub 2008 Jun 17.

PMID:
18559291
16.

Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial.

Nicolini H, Bakish D, Duenas H, Spann M, Erickson J, Hallberg C, Ball S, Sagman D, Russell JM.

Psychol Med. 2009 Feb;39(2):267-76. doi: 10.1017/S0033291708003401. Epub 2008 May 19.

PMID:
18485261
17.

Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies.

Davidson J, Allgulander C, Pollack MH, Hartford J, Erickson JS, Russell JM, Perahia D, Wohlreich MM, Carlson J, Raskin J.

Hum Psychopharmacol. 2008 Aug;23(6):519-26. doi: 10.1002/hup.949.

PMID:
18478624
18.
19.

Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.

Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK.

J Clin Psychiatry. 2001 May;62(5):350-7. Erratum in: J Clin Psychiatry 2001 Aug;62(8):658.

PMID:
11411817
20.

[Dynamic level observation of brain-derived neurotrophic factor in patients with first-episode generalized anxiety disorder].

Shen XH, Qian MC, Niu FR, Sun ST, Zhu YP, Yang JH, Lin M, Yu BR, Li L, Shen ZX.

Zhonghua Yi Xue Za Zhi. 2011 Nov 8;91(41):2939-41. Chinese.

PMID:
22333619
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk